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Imprinting is an epigenetic modification that is reprogrammed in the germ line and leads to the monoallelic expression of some genes.
Imprinting involves DNA methylation. Maternal imprint is reset during oocyte growth and maturation. In vitro maturation (IVM) of oocytes may,
therefore, interfere with imprint acquisition and/or maintenance. To evaluate if maturing human oocytes in vitro would be hazardous at the
epigenetic level, we first determined the methylation profile of the H19 differentially methylated region (DMR). The methylation status of the H19
DMR seems particularly vulnerable to in vitro culture conditions. We analyzed oocytes at different stages of maturation following IVM, germinal
vesicle (GV), metaphase I (MI), and metaphase II (MII), using the bisulfite mutagenesis technique. Our results indicated that the unmethylated
specific maternal profile for the H19 DMR was stably established at the GV stage. The majority of MI-arrested oocytes exhibited an altered
pattern of methylation, the CTCF-binding site being methylated in half of the DNA strands analyzed. Of the 20 MII oocytes analyzed, 15 showed
the normal unmethylated maternal pattern, while 5 originating from two different patients exhibited a methylated pattern. These findings highlight
the need for extended analysis on MII-rescued oocytes to appreciate the epigenetic safety of the IVM procedure, before it becomes a routine and
practical assisted reproductive procedure.
D 2005 Elsevier Inc. All rights reserved.Keywords: Human oocytes; In vitro maturation; Imprinting; H19; MethylationIVF (in vitro fertilization) patients are currently treated with
large doses of gonadotropins to induce superovulation, with an
accompanying risk of ovarian hyperstimulation syndrome,
particularly in patients with polycystic ovarian syndrome
(PCOS). Maturing oocytes in vitro (IVM) would drastically
reduce the amount of exogenous gonadotropin required and
avoid such ill effects and may also be a viable alternative to
cancellation of the IVF cycles in poor responders [1]. To date,
several births have been achieved from IVM human oocytes
[1–10]. However, pregnancy and live birth success rates
remain low following transfer of embryos derived from IVM
oocytes [11].0888-7543/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.Recent articles have associated ART (assisted reproduc-
tive technology) with an increased susceptibility to imprint-
ing errors, particularly an apparent increased frequency of
Beckwith–Wiedemann syndrome (BWS) [12,13] related to
abnormal imprinting of KCNQ1OT1 or H19 genes [14].
DNA methylation is an epigenetic modification that con-
stitutes a distinguishing mark on one parental allele to bring
about the sex-specific expression of imprinted genes. Prior
to the establishment of these sex-specific marks in the germ
line, imprints are erased very early, in primordial germ cells
as shown in the mouse [15–17]. Imprint acquisition occurs
in the postnatal growth phase of mouse oogenesis [18–20].
The erasure, establishment, and maintenance of imprints are
dynamic processes that must be correctly reprogrammed
with every reproductive cycle. Since the primary imprinting
process occurs fairly late in oogenesis [18,19], the question
of whether in vitro conditions for oocyte maturation can
support the establishment and/or maintenance of imprinting6) 417 – 426
www.el
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concerning the timing of imprint establishment in human
oocytes.
To evaluate the epigenetic status of human oocytes
following in vitro maturation, we first analyzed the
methylation profile of H19. The region controlling parent-
of-origin-dependent methylation (DMR, for differentially
methylated region) of IGF2/H19 contains binding sites for
the enhancer-blocking protein CTCF [21,22]. When pater-
nally inherited, the DMR sequence is methylated and
insulator activity is blocked so that IGF2 expression is
permitted while H19 is silenced. H19 represents a good
marker of epigenetic susceptibility to environmental injuries,
since the methylation status of the H19 DMR seems to be
particularly vulnerable to culture conditions [23] and in vitro
differentiation [24]. Culture of mouse embryos in the
presence of fetal calf serum is associated with a gain of
methylation on the maternal allele at the H19 DMR and a
decrease in the expression of H19 and in the developmental
capacity of the embryo [23]. Likewise, culture of mouse
embryonic stem (ES) cells induced biallelic methylation of
the H19 DMR associated with strong reduction of H19Table 1
Number and maturity of oocytes: comparison between in vivo and in vitro maturin
Cycle No. of oocytes retrieved No. of
cultureTotal Mature % mature
a 13 7 53.8 4
b 17 10 58.8 5
c 15 7 46.6 8
d 25 22 88 3
e 8 1 12.5 7
f 23 14 60.8 9
g 20 14 70 4
h 18 12 66.6 2
i 13 9 69.2 2
j 30 26 86.6 2
k 8 4 50 4
l 17 9 52.9 8
m 18 7 38.8 11
n 16 13 81.2 3
o 14 5 37.7 9
p 14 10 71.4 4
q 25 21 84 2
r 13 10 76.9 2
s 20 17 85 3
t 7 3 42.8 3
u 18 7 38.8 6
v 13 9 69.2 3
w 10 5 50 5
x 26 11 42.3 13
y 24 18 75 6
z 17 13 76.4 3
aa 24 3 12.5 21
ab 5 4 80 1
ac 14 10 71.4 4
ad 13 9 69.2 3
ae 27 19 70.3 6
Oocytes were retrieved from women undergoing ovarian stimulation. Immature o
Medicult maturing medium for 24 h. Their capacity to mature in vitro, i.e., to reacexpression and compromised development in the ES-cell-
derived fetuses [25]. In contrast, human ES cells display a
stable methylation profile [26]. This discrepancy between
human and mouse shows that it is important to perform
studies on human material, even though procedural con-
straints may result in low sample number and certain
experimental questions remaining unanswered. In the mouse,
hypermethylation of the H19 DMR has been associated with
decreased developmental competence [27,28]. In humans,
hypermethylation of the H19 DMR, particularly at the sixth
CTCF-binding site, has been correlated with a variety of
pathologies including colon cancer [29], osteosarcoma [30],
biparental complete hydatiform moles [31], Wilms’ tumor
[32], and BWS [14]. Increased tumor risk for BWS patients
has been shown to correlate with H19 hypermethylation
[32–34]. In this context, the higher incidence of BWS
reported in children conceived by ART [12–14] supports the
need for studies on the epigenetic status of H19 in human
oocytes following IVM.
We have designed primers to amplify bisulfite-converted
DNA in a region comprising the sixth of the seven CTCF-
binding sites described in humans. This CTCF-binding siteg process
oocytes
d in vitro
No. of oocytes following IVM
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ocytes at GV (germinal vesicle) or MI (metaphase I) stage were cultured in
h MII (metaphase II stage) was then evaluated.
Table 2
Maturation of human oocytes cultured for 24 h in Medicult maturing medium
D0 D1
GV MI MII
Oocytes, total number: 154 31 (20.2%) 56 (36.3%) 67 (43.5%)
Cycles, total number: 31
GV, total number:
92 (59.7%)
31 (33.7%) 22 (23.9%) 39 (42.4%)
MI, total number:
62 (40.3%)
— 34 (55%) 28 (45%)
Oocytes were retrieved immature at D0 from stimulated cycles, either at
germinal vesicle stage (GV) or at metaphase I stage (MI). They were cultured
for 24 h and collected on D1 at GV, MI, or MII stage. MII corresponds to the
extrusion of the first polar body; these oocytes are at metaphase II stage and
considered mature.
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region is abnormally methylated on the maternal allele in
Wilms’ tumor [36]. We have analyzed oocytes at different
stages following in vitro maturation: at metaphase II (MII)Fig. 1. (A) Diagram of the IGF2/H19 locus. DMR, differentially methylated region. T
and is boxed in the enlarged diagram. Locations of PCR primers used for cloning
Accession No. AF087017. Circles represent the locations of CpG dinucleotides. (B)
6328 in adult lymphocytes from peripheral blood, from patient aa or from normal fert
(a, 10 cells; b, 20 cells). Black circles represent methylated CpG’s, white circles re
methylation with the number of clones showing a given pattern indicated on the rior blocked at the germinal vesicle (GV) or metaphase I (MI)
stage.
Results
In vitro maturation of oocytes
The total number of oocytes retrieved per patient varied
from 5 to 30 (Table 1). The oocytes utilized in this study were
considered fully grown as their average size was 142.5 T 4.6
Am. The number of oocytes cultured in vitro per patient varied
from 1 to 21, corresponding to oocytes that were not mature the
day of retrieval (D0), at the end of the stimulation protocol. The
number of oocytes that reached the MII stage in vitro varied
from 0 to 10. There is no apparent correlation between the
capacity to mature in vitro compared to in vivo for each
particular patient.
As shown in Table 2, a total of 154 oocytes,
corresponding to 31 cycles, survived following IVM and
were utilized in this study. On day D0, 92 oocytes (59.7%he sixth CTCF-binding site is depicted as a gray diamond in the upper diagram
are indicated by numbered arrows. Base numbering is according to GenBank
Methylation status of each CpG in the H19 upstream region from base 5999 to
ile persons (P, corresponding to two pooled blood samples) and in cumulus cells
present unmethylated CpG’s. Each line denotes an individual pattern of DNA
ght.
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total) at MI. Following IVM (at D1), of the first group, 31
oocytes (33.7%) remained arrested at GV, while 22 (23.9%)Fig. 2. Methylation status of individual DNA strands in the H19 upstream DMR i
mutagenesis analysis. Unmethylated CpG’s are represented as empty circles, while
pattern of DNA methylation with the number of clones showing a given pattern indic
a particular patient) and O the number of oocytes per pool treated together. The devel
retrieval. Oocytes were pooled at day 1 (D1) following IVM and before freezing. O
were pooled and treated together. (A) a: Control GVoocytes (germinal vesicle stage)
IVM. (B) Oocytes were at GVat D0 and reached MI or were at MI at D0 and remaine
reached MII following IVM.reached MI and 39 (42.4%) MII stage. Of the second group,
34 oocytes (55%) remained arrested at MI, while 28 (45%)
matured up to MII.n oocytes cultured for 24 h in a maturing medium, as determined by bisulfite
methylated CpG’s are depicted as filled circles. Each line denotes an individual
ated in column N. P indicates the code number for each cycle (corresponding to
opmental stage of the oocytes, GV, MI, or MII, was determined at D0, the day of
ocytes from the same patient that were at the same stage of development at D1
were frozen at D0. b: Oocytes were at GVat D0 and remained at GV following
d at this stage following IVM. (C) Oocytes were either at GVor at MI at D0 and
Fig. 2 (continued).
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The methylation status of the IGF2/H19 DMR was
determined by cloning and sequencing of bisulfite-treated
DNA. Our bisulfite sequencing protocol was validated on
genomic DNA extracted from human blood. An average
methylation pattern of 49.8% was obtained after several
independent experiments (Fig. 1B), indicating no bias toward
methylated or unmethylated alleles. Pooling 100 or more
oocytes from several patients would be reliable but would
certainly not be informative at the patient level and unhelpful
from a clinical point of view. Therefore we chose to analyze
pools of a small number of oocytes (1 to 8 oocytes/pool) from
the same patient, at the same stage of maturity following
IVM. To attest to the viability of our bisulfite sequencing
analysis on a limited amount of DNA, we performed
additional controls on pools of 10 to 20 human cumulus
cells. Both the maternal and the paternal alleles could be
amplified (Fig. 1B).
Methylation of the IGF2/H19 DMR in oocytes
Nine to 17 clones were sequenced for each single oocyte or
pool. The efficiency of PCR amplification was 36% (a signal
was obtained in 21 samples of 58 assayed). Blanks (pGEM-T
plasmid alone) were included in each bisulfite sequencing
experiment and the contamination percentage was less than 2%
(1 sample of 58). DNA destruction is very important following
bisulfite treatment, but it is very likely exerted randomly.
Therefore, in a given sample, the number of alleles left intact
may vary from 0 to all the alleles initially present. This helps us
understand why 64% of the samples assayed failed to give any
amplified material following a nested PCR. Therefore, the
results are presented in terms of allelic profile, independent of
the number of alleles presumably present in the sample, since
the number of DNA strands left intact in each sample cannot be
determined and since it is impossible to differentiate if two
identical patterns are derived from two different originaltemplates or both result from the amplification of the same
DNA strand.
Oocytes at GV stage
The GV oocytes that were frozen on day 0 (patients af and
ag) showed only one type of allele with a 100% unmethylated
pattern of methylation. Following IVM, six oocytes from two
different patients (m and x) also showed a unique allelic
unmethylated profile, while a pool of two oocytes from a third
patient (r) showed a heterogeneous pattern of methylation with
seven different allelic profiles from the eight DNA strands
initially present in the sample (Fig. 2A).
Oocytes at metaphase I stage
MI oocytes at day 1 originated from either GV or MI
oocytes at day 0. Only one allelic profile with 100% of the
CpG sites being unmethylated was found in 5 oocytes
originating from GV oocytes (patients v and w) and 3
oocytes originating from MI oocytes (patient aa), as shown
in Fig. 2B. A heterogeneous figure was found in 14 oocytes,
3 originating from GV stage (patient u) and 11 originating
from MI stage (patients o, b, and aa) at day 0, with alleles
showing a variable degree of methylation from 0 to 21 of
their CpG sites being methylated (Fig. 2B). In these samples
showing heterogeneous methylation at the H19 DMR, the
CTCF-binding site was methylated in 7 of 13 distinguishable
allelic profiles.
Oocytes at metaphase II stage
A 100% unmethylated pattern was found in seven samples
including 15 oocytes (Fig. 2C), 13 of them originating from
GVoocytes (patients s, x, ab, and ad) and the other 2 from MI
oocytes (patients s and ac) at day 0. Three oocytes from the
same patient (y) showed only one allelic pattern, 100%
methylated, while 2 oocytes from patient ae exhibited one
unmethylated allelic pattern and another one with 20 methyl-
ated CpG’s of 21.
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To validate the sequencing results on a limited number of
copies and to confirm that the cloning was not biased, we
carried out restriction analysis, cutting the mutagenized
DNA with enzymes that cleave only the methylated
templates (results are given in Fig. 3). This was done on
samples 34, 40, 41, and 46 by carrying out restriction
digests on the same bisulfite-treated PCR amplification
products that were used for the cloning and sequencing
shown in Fig. 2. As a control for the efficacy of the
bisulfite treatment, Tru1I cuts the PCR product at a position
corresponding to a thymidine that is a cysteine in the native
DNA sequence. The cut generates three fragments of 237,
56, and 37 bp, only if the bisulfite treatment is effective, asFig. 3. Methylation status of the H19 DMR in oocytes following IVM, by restrictio
were used for the cloning and sequencing shown in Fig. 2 were digested by the restri
bisulfite treatment is effective (native DNA: CCAA), and enzymes that cleave only
6193, and 6281; TaqI (T/CGA), which cleaves at position 6224; and Hin6I (G/CG
Accession No. AF087017. For each sample a graph represents the results of the sequ
methylated CpG). Trails are as follows: 1 for uncut PCR product, 2 for Tru1I digecan be seen in all the sample digests. Digestion of PCR
product 41 with either Bsh1236I, TaqI, or Hin6I revealed
only the uncut product (Fig. 3), indicating no methylation.
Digestion of PCR product 34 with Bsh1236I resulted in the
appearance of digestion products of 193 and 137 bp
corresponding to the cut of the first and/or the second
Bsh1236I sites, indicating that CpG’s 8 and 9 were
methylated and that the third restriction site for Bsh1236I
contains unmethylated CpG’s (Fig. 2B) that do not allow the
digestion to proceed. Digestion with Hin6I and TaqI did not
proceed, corresponding respectively to the nonmethylation of
CpG’s 10 and 12. Sample 40 showed both uncut and
digested products with the same ratio for all three enzymes
cutting within CpG sites, indicating that both methylated
and unmethylated templates were present in a similarn enzyme analysis. The same bisulfite-treated PCR amplification products that
ction enzyme Tru1I (T/TAA), which cuts at positions 6235 and 6272 only if the
the methylated template: Bsh1236I (CG/CG), which cleaves at positions 6191,
C), which cleaves at position 6191. Base numbering is according to GenBank
encing as shown in Fig. 2 (empty circles for unmethylated CpG, filled circles for
st, 3 for Bsh1236I digest, 4 for TaqI digest, and 5 for Hin6I digest.
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products with the same ratio for Bsh1236I and TaqI,
indicating that, at these sites, both methylated and unmethy-
lated templates were present in similar proportions. By
contrast, Hin6I did not cleave this product, corresponding to
the nonmethylation of CpG 10, as observed from sequenc-
ing. The results of restriction enzyme analysis are compa-
rable to those obtained from sequencing (Fig. 2), given that
some products of restriction analysis are too small to
visualize on agarose gels and that only a limited number
of sites can be assayed with this technique.
Discussion
IVM has been developed in several ART centers the past 10
years. Outcomes indicated that 62 to 80% of immature oocytes
reached MII by 48–54 h of culture, independent of patient
history (normal, poor responders, or PCOS patients, stimulated
or unstimulated cycles) [1–10]. Prolonged culture (up to 42–
48 h) increased maturation rate but lowered development to
blastocyst [2] and altered methylation at Peg1 [37]. Therefore,
we used a 24-h culture IVM protocol. The maturation
efficiency we obtained (42.4 to 45%) was comparable to that
observed by others with oocytes from stimulated cycles (34 to
50.5%) [7,9].
The acquisition of developmental competence by oocytes,
which is poorly understood in any species, includes acquisition
of the maternal imprint. In the mouse, maternal imprinting
occurs during oocyte growth [18,19] and methylation acquisi-
tion correlates with an increase in oocyte diameter [38].
Therefore, we retained only oocytes that had reached the size
of normal fully grown GVoocytes (between 120 and 150 Am in
humans). Preliminary studies in the mouse suggest that a 12-
day culture period can lead to loss of methylation at Igf2 and
Peg1 and gain of methylation at H19 [24]. To clarify the
process of imprint establishment and maintenance, and to
assess whether the shorter time required for IVM might also
affect imprints, we have analyzed the methylation status of the
H19 DMR in human oocytes arrested at different stages of their
maturation following a 24-h incubation in a maturing medium.
Data on H19 [39,40] and on Snrpn [20] indicate that there
are sex-specific differences in the developmental timing of the
establishment of methylation imprints in the two germ lines.
Preexisting methylation imprints are erased in human fetal
spermatogonia and the typical paternal methylation profile of
H19 first appears in a subset of adult spermatogonia and then
is maintained up to the spermatozoon [41]. In experimental
mouse parthenogenetic embryos, H19 was expressed equiva-
lently by both the nongrowing and the fully grown oocyte-
derived alleles, indicating that H19 imprinting is established
early in mice [42]. Our results show that most oocytes at GV
exhibited the expected unmethylated profile for H19 maternal
alleles. This suggests that erasure of paternal imprint is
complete and that the maternal unmethylated status of H19
is stably established at this stage, before meiosis resumption.
By contrast, in benign ovarian teratomas, the allele of paternal
origin showed various degrees of methylation, suggesting thatthe primary imprint of H19 was not erased until late oogenesis
[43]. This apparent discrepancy may be attributed to the
process of tumorigenesis itself, since alteration of H19
imprinting commonly occurs in tumors. The heterogeneous
pattern of methylation observed in a pool of two GV oocytes
could correspond to an error in the genomic imprinting
process, although contamination with diploid cumulus cells
cannot be completely excluded. Anyhow, special care was
taken to ensure complete removal of follicular cells, and if
oocyte pools were contaminated with diploid cumulus cells,
we could not explain the presence of completely unmethylated
patterns that we observed.
The majority of MI-arrested oocytes, especially those that
were collected as MI oocytes and remained as such even after 24
h culture, exhibited a methylated pattern, particularly at the
CTCF-binding site. The epigenetic alteration observed in MI-
arrested oocytes may account in part for the impaired perfor-
mance of ICSI (Intracytoplasmic Sperm Injection) with MI
compared with ICSI of rescued IVMMII oocytes or MII oocytes
[44]. Considering that loss of differential methylation at theH19
DMR is associated with a large variety of pathologies, the use of
MI immature oocytes for ICSI is not to be recommended.
Most of the MII-rescued oocytes showed the normal
unmethylated maternal pattern, while five oocytes recovered
from two different patients exhibited a methylated pattern.
Interestingly, mice having their CTCF expression cut off
using RNA interference produced oocytes bearing a hyper-
methylated H19 profile associated with a significant
decrease in the developmental capacity of the resulting
embryos [27]. Methylation at the H19 locus has been
described in fully grown mouse oocytes produced by in
vitro folliculogenesis from early preantral follicles [24]. The
authors concluded that a dysregulation of the process of
primary imprinting during oocyte growth was the result of
in vitro folliculogenesis. Preimplantation mouse embryos
cultured in the presence of serum displayed a decreased
expression of H19 associated with a gain of methylation on
the maternal allele [23] and a lower developmental potential.
In humans, studies of female germ cells are very limited by
ethics and little is known of the timing of methylation imprints.
There are only two contradictory reports on the maternal
methylation imprinting of the SNRPN gene. The first indicates
that the methylation imprint is established during or after
fertilization [45], while the second showed complete methyl-
ation of the DMR region of the SNRPN gene in GV and
rescued MII oocytes [46].
Considering that most of the MII-rescued oocytes in our
experiments, as well as in those performed by Geuns et al. [46],
showed a normal maternal pattern of methylation, and the fact
that SNRPN and H19 sex-specific methylation profiles seem to
be already established at the GV stage, the high percentage of
altered methylated profiles found at the H19 DMR locus in MI
oocytes and in some GVor MII oocytes could be the result of an
impairment of imprint establishment or erasure that occurred in
vivo during oocyte growth, rather than an alteration of the
imprint induced by in vitro culture for 24 h. However, since the
paternal and the maternal alleles are not distinguishable, an
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methylation profiles observed in MI oocytes suggest that a link
may exist between the capacity to resume meiosis and the
epigenetic maturity of oocytes. This hypothesis is sustained by
the following observations: (1) The percentage of MII oocytes
retrieved from patient aa at the end of an ovarian stimulation was
extremely low and this following several stimulation cycles
(data not shown), and the majority of the oocytes arrested at MI
following IVM exhibited a disturbed pattern ofmethylation (Fig.
2B). ICSI was performed with the eight rescued MII oocytes
from patient aa, but no pregnancy could be obtained following
transfer. On the other hand, lymphocytes from this patient
exhibited a normal biallelic pattern of methylation (Fig. 1B). (2)
When MI oocytes retrieved at D0 were able to mature in vitro,
they gave rise to MII oocytes exhibiting a normal unmethylated
pattern (patients ac and s, Fig. 2C).
In conclusion, this is the first study that analyzed the
epigenetic status of human oocytes at different stages
following IVM on an appreciable cohort. We have confirmed
that analysis of a small number of cells is informative if
conclusions are made respecting the limitations of the
procedure. The result of two patients exhibiting methylation
at the H19 locus in MII-rescued oocytes may serve as a
warning before IVM becomes a routine and practical assisted
reproductive procedure. However, extended analysis of a
significant number of MII-rescued oocytes is needed to
determine whether the IVM process induces an increased
incidence of hypermethylation at the H19 locus. Because
access to human oocytes is limited, studies on human oocytes
will necessarily involve a smaller number of samples than
studies on animal models. Even though studies on animal
models are a valuable source of knowledge, they cannot
substitute for studies on humans. This is particularly true in
studies dealing with DNA methylation analysis, since a recent
work established the nonconservation of mammalian preim-
plantation methylation dynamics, highlighting the pitfalls of
interspecific extrapolation [47].
Material and methods
Source of human oocytes and IVM
IVM oocytes from unstimulated patients are not available for ethical
reasons. The oocytes utilized in this study were aspirated from ovaries of
women undergoing ovarian stimulation for ICSI, using a standard long-term
stimulation protocol with follicle-stimulating hormone (FSH) and human
chorionic gonadotropin (hCG). The day of retrieval (day 0), 35 h after hCG
administration, oocytes were denuded of cumulus cells by repeated pipetting
in a hyaluronidase solution (150 units, type VIII; Sigma) and then washed
in several PBS baths. Particular care was taken to ensure removal of all
somatic cells. Pools of 10 and 20 cumulus cells were frozen. Mature
oocytes (MII) were selected for ICSI. A total of 166 immature fully grown
oocytes (120 to 150 Am in humans), retrieved from 31 patients (average age
31 T 8 years) in 33 ovarian stimulation cycles, arrested either at germinal
vesicle stage or at metaphase I, were cultured in IVM System (MediCult,
Syllinge, Denmark), supplemented with FSH, hCG, and 10% patient serum,
for 24 h under 5% CO2 in air, at 37-C. Institutional approval and written
consent from all patients were obtained prior to placing oocytes in culture.
GV oocytes from patients af and ag were frozen directly on day 0. After in
vitro culture for 24 h (at day 1), the oocytes were either matured at MII orimmature, arrested at GV or MI. For a given patient, oocytes at the same
stage of maturity were pooled (1 to 8 oocytes) and frozen.
DNA methylation analysis
Bisulfite sequencing
The methylation profile of H19 was determined by bisulfite mutagenesis
and sequencing. Oocytes were thawed and placed in a lysis solution containing
50 mM EDTA, 50 mM Tris, pH 8, 3 Ag of DNA carrier (pGEM-T plasmid;
Promega, France), and 0.14 Ag/Al proteinase K, in a final volume of 100 Al, and
incubated for 2 h at 55-C. Following the addition of 3 Ag of DNA carrier and
alkaline denaturation, DNAwas incubated in 3 M sodium bisulfite containing 1
mM hydroquinone for 16 h at 50-C, in a final volume of 500 Al. Modified DNA
was purified using the Wizard DNA Clean-Up System (Promega) and eluted in
200 Al of sterile water. Desulfonation in 0.3 M NaOH and precipitation with
ethanol followed bisulfite treatment. DNA was resuspended in water and
utilized for PCR amplification. Dry pellets of blood cells corresponding to 30
Al of blood were identically treated, except that DNA carrier was omitted.
We amplified by nested PCR a 330-bp region comprising the sixth CTCF-
binding site and encompassing 21 CpG’s in the H19 DMR (Fig. 1A): forward
external primer, 5V-TTGATTTATTTTAGGGTGTATTGTTGAAG-3V; reverse
external primer, 5V-ACTCCTATAAATATCCTATTCCCAAATAACCCC-3V;
forward internal primer, 5V-AATAATGAGGTGTTTTAGTTTTATGGATG-3V;
reverse internal primer, 5V-TCCTATAAATATCCTATTCCCAAATAACC-3V.
The primers were designed to amplify mutagenized DNA at the single-cell
level. The resulting PCR products were subcloned into pGEM-T plasmid
(Promega) and sequenced (Biofidal, Lyon, France).
Restriction analysis
Approximately 100 ng of the same purified PCR used for cloning and
sequence analysis was digested with Tru1I (recognition site T/TAA), Bsh1236I
(recognition site CG/CG), TaqI (recognition site T/CGA), and Hin6I
(recognition site G/CGC). Enzymes were purchased from Fermentas (France).Acknowledgments
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